NRG Oncology

Dr. Neil Desai discussed the role of ADT and genomic risk stratification for unfavorable intermediate-risk prostate cancer at the 2024 ASTRO annual meeting, emphasizing the use of advanced risk classifiers like Decipher, Prolaris, Oncotype DX GPS, and MMAI to guide treatment decisions, including the duration of ADT and RT intensity.

The NRG-HN005 phase II/III trial failed to meet non-inferiority criteria for p16+ oropharyngeal cancer treatments, affirming traditional chemoradiation's effectiveness and setting a high bar for future deintensification studies.

A trial for de-intensified radiation treatments in HPV-associated oropharyngeal cancer was halted due to 98% two-year progression-free survival in the control arm, indicating chemoradiation's high efficacy. De-intensified treatments with lower radiation and immunotherapy did not match this success, necessitating further research to balance efficacy and side effects.

Cognitive side effects from radiation therapy for brain metastases are fully reversible, especially with conformal techniques, according to a pooled analysis of three phase III trials. 42% of patients fully recovered cognitive function within a year, with conformal radiation showing higher recovery rates than whole-brain radiation therapy.

Cognitive side effects from radiation therapy for brain metastases may fully recover, especially with conformal radiation techniques, according to a pooled analysis of three Phase III trials. 38-42% of patients showed full cognitive recovery within a year, with 73-76% improving on one or more cognitive tests. Conformal radiation techniques like SRS were more effective in promoting recovery.

Phase 3 RCT comparing SBRT to hypofractionated CRT in stage I NSCLC found no significant difference in 3-year local control, with limited toxic effects in both groups, including central tumors.

LeJeunesse, diagnosed with de novo metastatic breast cancer, advocates for cancer research through her podcast 'Cancer for Breakfast' and attends events like the Value in Cancer Care Summit. She is a clinical trials enthusiast and collaborates with her oncologist, Dr. Rachel Yung, who highlights the importance of patient involvement in research design. LeJeunesse also created the Breast Cancer Care-a-van, a mobile distribution center for cancer information and support.